🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Esotid 20 Capsule is a medication that lowers the amount of acid produced in your stomach. It is used to treat heartburn, acid reflux, and food pipe issues. It is also employed in the prevention and treatment of stomach ulcers. You should take Esotid 20 Capsule as directed by your doctor.
Caution is advised when consuming alcohol with Esotid 20 capsules. Please consult your doctor.
Esotid 20 capsules may be unsafe to use during pregnancy. Although there are limited studies on humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing them to you. Please consult your doctor.
Esotid 20 Capsule is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
It is not known whether Esotid 20 Capsule alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Esotid 20 Capsule is safe to use in patients with kidney disease. No dose adjustment of the Esotid 20 Capsule is recommended. However, inform your doctor if you have any kidney disease.
Esotid 20 Capsule should be used with caution in patients with severe liver disease. A dose adjustment of Esotid 20 Capsule may be needed. Please consult your doctor.
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Esotid 20 Capsule is to be taken empty stomach.
Esotid 20 Capsule is a proton pump inhibitor (PPI). It works by reducing the amount of acid in the stomach which helps in relief of acid-related indigestion and heartburn.
If you miss a dose of Esotid 20 Capsule, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.
Esomeprazole is indicated:
Esomeprazole is a proton pump inhibitor that reduces stomach acid production by specifically inhibiting the H+/K+-ATPase in the gastric parietal cell. Esomeprazole (S-isomer of omeprazole) is the first proton pump inhibitor with a single optical isomer that outperforms racemic proton pump inhibitors in acid control.
For absorption, esomeprazole capsules contain an enteric-coated pellet formulation of esomeprazole magnesium. Peak plasma levels (Cmax) occur approximately 1.5 hours after oral administration (Tmax). When the dose is increased, the Cmax rises proportionally, and the area under the plasma concentration-time curve (AUC) rises three times from 20 to 40 mg. With repeated once-daily administration, systemic bioavailability is around 90%, compared to 64% with a single dose. In comparison to fasting conditions, the AUC after a single dose of esomeprazole is reduced by 33-53 percent after food ingestion. Esomeprazole should be taken at least one hour before meals. In 97 percent of cases, esomeprazole is linked to plasma proteins. Plasma protein binding is constant over a concentration range of 2 20 mmol/L. At a steady state, the apparent volume of distribution in healthy individuals is around 16 L. In the liver, the cytochrome P450 (CYP) enzyme system extensively metabolizes esomeprazole. Metabolites of esomeprazole have no anti-secretory activity. The majority of esomeprazole metabolism is carried out by the CYP2C19 isoenzyme, which generates the hydroxy and desmethyl metabolites. The rest is reliant on CYP3A4, which generates the sulphone metabolite. The plasma elimination half-life of esomeprazole is approximately 1-1.5 hours. Less than 1% of the parent medication is eliminated in the urine. Approximately 80% of an oral dose of esomeprazole is eliminated as inactive metabolites in the urine, with the remainder detected as inactive metabolites in the feces.
Digoxin-induced cardiotoxicity is more likely. Diuretics increase the risk of hypomagnesemia. Warfarin may cause an increase in INR and prothrombin time. Tacrolimus, saquinavir, and methotrexate serum concentrations may be increased. Drugs metabolized by CYP2C19 may be eliminated more slowly (e.g. diazepam). Ketoconazole, erlotinib, and Fe salts' bioavailability may be reduced. Possibly fatal: Rilpivirine, atazanavir, and nelfinavir serum concentrations and pharmacological effects may be reduced. Clopidogrel's antiplatelet effects may be reduced.
Esomeprazole is not recommended for patients who have a history of hypersensitivity to any component of the formulation or substituted Benzimidazoles.
In pregnant women, there are no appropriate and well-controlled trials. Teratogenic effects have not been discovered in animal investigations. Esomeprazole excretion in milk has not been examined. If the use of esomeprazole is deemed necessary, breastfeeding should be stopped.
Store in a dry location at a temperature not exceeding 30°C. Keep out of direct sunlight and dampness. Keep out of children's reach.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.